Pharmafile Logo

Forging innovative solutions by merging art and science

In the latest episode of Impetus Digital’s Fireside Chat, we dive into the concept of merging art and science with Ariel Garten, Founder & Chief Evangelism Officer at Muse. Ariel Garten is the Founder of InteraXon, makers of Muse: the award-winning headband that makes meditation easier. She studied neuroscience at the University of Toronto, worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis, and was also a therapist in private practice. Ariel’s uncommon combination of science and art is integral to the design of Muse and to InteraXon’s unique approach to brain-sensing technology.

In this webinar, we explore many exciting topics such as the idea of whether art and beauty can be broken down into biological codes, the resurgence of meditation, the concept of “Pause” during COVID-19 and many more meaty subjects. You can also listen to the podcast version here. 


This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive...

No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the...

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.